The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
Reintroduction of the Cyclin A2 gene enables adult human cardiomyocytes to divide, producing functional daughter cells and promoting heart repair. The therapy uses a replication-deficient adenoviral ...
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
Exposure to endocrine-disrupting bisphenol chemicals—including bisphenol A (BPA), bisphenol S (BPS), and bisphenol F (BPF)—was associated with more than 127 million cases of obesity, type 2 diabetes ...
SJS/TEN survivors face long-term sequelae, including systemic organ damage and psychological challenges like PTSD, impacting quality of life. Inadequate post-discharge support leads to feelings of ...
Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.
Remibrutinib showed rapid and sustained efficacy in CSU, with significant symptom reduction by week 2, maintained over 52 weeks. The pooled analysis of REMIX-1 and REMIX-2 trials highlighted ...
Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.
For payers, the case for patient engagement in CKD is compelling. It improves outcomes, reduces costs, supports quality metrics and star ratings, and strengthens member satisfaction. But it doesn’t ...
Panelists discuss how the Inflation Reduction Act (IRA) introduces landmark changes to drug pricing through its negotiation ...
Panelists discuss how step edits hinder timely cancer treatment and urge policies that prioritize evidence-based access over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results